Literature DB >> 11598887

The role of cytokines in cancer-related fatigue.

R Kurzrock1.   

Abstract

Fatigue is prominent in cancer patients and probably multifactorial in origin. Factors contributing to fatigue include anemia, weight loss, fever, pain, medication, and infection. In cancer patients, many of these factors are influenced by a frequently disrupted balance between endogenous cytokine levels and their natural antagonists. Indeed, cancer cells and the immune system appear to overexpress a range of cytokines in patients with malignancies. Some of these cytokines act as autocrine or paracrine growth factors for the neoplastic tissue while simultaneously causing secondary symptoms related to fatigue. For instance, cancer-associated anemia may be due to a blunted erythropoietin response and/or cytokines (interleukin-1 [IL-1], IL-6, tumor necrosis factor-alpha [TNF-alpha]), which suppress erythropoiesis. Cancerous cachexia, a wasting syndrome and a hallmark of cancer, can be attributed to loss of appetite or enhanced energy expenditure. Several different interleukins, as well as TNF, interferon-gamma, and leukemia inhibitory factor, act as cachectins in animal models. Similarly, fever and night sweats are influenced by pyrogenic cytokines. Recently, molecules that function as cytokine antagonists have been identified. These molecules may be exploitable in combating the components of cancer-related fatigue, and may inhibit tumor growth as well. Copyright 2001 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11598887     DOI: 10.1002/1097-0142(20010915)92:6+<1684::aid-cncr1497>3.0.co;2-z

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  67 in total

1.  Cancer fatigue--more data, less information?

Authors:  Susan B LeGrand
Journal:  Curr Oncol Rep       Date:  2002-07       Impact factor: 5.075

2.  Fatigue and sleep quality are associated with changes in inflammatory markers in breast cancer patients undergoing chemotherapy.

Authors:  Lianqi Liu; Paul J Mills; Michelle Rissling; Lavinia Fiorentino; Loki Natarajan; Joel E Dimsdale; Georgia Robins Sadler; Barbara A Parker; Sonia Ancoli-Israel
Journal:  Brain Behav Immun       Date:  2012-03-02       Impact factor: 7.217

3.  Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant.

Authors:  Willem W Overwijk; Karin E de Visser; Felicia H Tirion; Laurina A de Jong; Thijs W H Pols; Yme U van der Velden; Jasper G van den Boorn; Anna M Keller; Wim A Buurman; Marc R Theoret; Bianca Blom; Nicholas P Restifo; Ada M Kruisbeek; Robert A Kastelein; John B A G Haanen
Journal:  J Immunol       Date:  2006-05-01       Impact factor: 5.422

Review 4.  Molecular epidemiology, cancer-related symptoms, and cytokines pathway.

Authors:  Cielito C Reyes-Gibby; Xifeng Wu; Margaret Spitz; Razelle Kurzrock; Michael Fisch; Eduardo Bruera; Sanjay Shete
Journal:  Lancet Oncol       Date:  2008-08       Impact factor: 41.316

Review 5.  Antibody-cytokine fusion proteins: applications in cancer therapy.

Authors:  Elizabeth Ortiz-Sánchez; Gustavo Helguera; Tracy R Daniels; Manuel L Penichet
Journal:  Expert Opin Biol Ther       Date:  2008-05       Impact factor: 4.388

6.  Cancer-related symptom clusters, eosinophils, and survival in hepatobiliary cancer: an exploratory study.

Authors:  Jennifer L Steel; Kevin H Kim; Mary Amanda Dew; Mark L Unruh; Michael H Antoni; Marion C Olek; David A Geller; Brian I Carr; Lisa H Butterfield; T Clark Gamblin
Journal:  J Pain Symptom Manage       Date:  2010-05       Impact factor: 3.612

Review 7.  The pathophysiology of cancer-related fatigue: current controversies.

Authors:  C M O'Higgins; B Brady; B O'Connor; Declan Walsh; R B Reilly
Journal:  Support Care Cancer       Date:  2018-06-30       Impact factor: 3.603

8.  The effect of interleukin-1 blockade on fatigue in rheumatoid arthritis--a pilot study.

Authors:  Roald Omdal; Ragnar Gunnarsson
Journal:  Rheumatol Int       Date:  2004-04-08       Impact factor: 2.631

Review 9.  Pro-inflammatory cytokine-mediated anemia: regarding molecular mechanisms of erythropoiesis.

Authors:  F Morceau; M Dicato; M Diederich
Journal:  Mediators Inflamm       Date:  2010-03-01       Impact factor: 4.711

10.  Cooperation between monocytes and breast cancer cells promotes factors involved in cancer aggressiveness.

Authors:  E Blot; W Chen; M Vasse; J Paysant; C Denoyelle; J-Y Pillé; L Vincent; J-P Vannier; J Soria; C Soria
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.